Pharmaceutical

First bellwether trial in Xarelto MDL pushed back to April

xarelto 375x210 First bellwether trial in Xarelto MDL pushed back to April The first bellwether trial in the massive Xarelto multidistrict litigation (MDL) initially scheduled to be tried in in February has been pushed back another month at the request of both plaintiffs and defendants. The first Xarelto bellwether trial was initially set for February in Louisiana’s Eastern District. But with the NBA All-Star game moved to New Orleans and the usual congestion from Mardi Gras, Judge Eldon E. Fallon was prompted to push the start date to March.

Now, by agreement of all parties, Judge Fallen has postponed the trials yet another month, to April. The updated schedule is as follows:

April 24, 2017 in the Eastern District of Louisiana – the case Joseph Boudreaux Jr., who claims taking Xarelto for the treatment of atrial fibrillation caused him to suffer internal bleeding and require multiple blood transfusions.

May 30, 2017 in the Eastern District of Louisiana – the case of Joseph Orr, the husband of a woman who took Xarelto for a month before dying of a brain bleed.

June 2017 (TBD) in the Southern District of Mississippi – the case of Dora Miingo, who claims she suffered gastrointestinal bleeding after taking Xarelto to treat blood clots.

July 2017 (TBD) in the Northern District of Texas – the case of William Henry, a man who died from gastrointestinal bleeding after taking Xarelto to prevent strokes caused by atrial fibrillation.

More than 15,000 cases are pending in the Xarelto multidistrict litigation. The lawsuits claim that Xarelto makers Johnson & Johnson’s Janssen Pharmaceuticals and Bayer did not adequately warn that the blood thinner could cause serious and uncontrolled bleeding. They also accuse the manufacturers of marketing the drug before there was an antidote available to reverse the bleeding effects of the drug in the event of a bleeding emergency.

Source: MENA-Financial Network